As always, we have the most interesting (and important) news from the pharmacy compounding world, plus this episode we’ve got a deep dive into a future for peptides that protects patients while giving them access to the medications they want and need. Links from the episode Overview of the peptides issue (and recommendations): a4pc.org/peptides Overview of the ADT/DTE issue (and recommendations): a4pc.org/dte APC letter to California BoP about proposed out-of-state fee changes (1-page PDF): https://fllw.me/3Ued75S Washington Post story on potential (temporary) loosening of peptide regs: https://archive.is/fXroE Join APC: https://a4pc.org/join

Peptides. Animal-derived thyroid products. The perils of not documenting enough. A new recommendation for state regulation. And more. Besides the most interesting (and important) news from the pharmacy compounding world, this episode we’ve got a deep dive into the unique tax issues compounders face — which can be pretty darned daunting. Links from the episode APC issue brief on peptide compounding (two-page PDF): https://fllw.me/47mZu7b Citizen petition to FDA on compounding ADT (83-page (!) PDF): https://fllw.me/3VeA9tw FDA’s proposed GFI 256B — info and a chance to comment: https://www.regulations.gov/search?searchTerm=FDA-2018-D-4533 APC’s exclusive processing rates: https://apcpayments.com NABP’s model pharmacy act: https://nabp.pharmacy/members/board-resources/model-pharmacy-act-rules/ Sykes & Company Pharmacy Accounting Services: https://www.sykes-cpa.com/compounding-pharmacy-services

This episode looks at some smart ways to regulate pharmacy when it comes to med spas and pop-up clinics — ways that won’t cut patients off from their meds. We also look at the latest news on the thyroid-extract front, what’s happening with peptide compounding, and a bill in California that could bode well for pharmacists nationwide. Then we talk with Kristen Jones, PharmD, from Pharmacists Mutual about how insurance companies view compounding, and why compounders are taking a bigger risk than they might realize if they’re compounding peptides. Pharmacists Mutual: https://pmuw.com Join APC: a4pc.org/join Stay up to date on these topics and more at: a4pc.org/news

In this episode, Andrew Kantor is joined by federal lobbyist David Pore and PCCA's Amy Shank to examine the proposed SAFE Act and its potential impact on compounding pharmacies. The discussion explores concerns that the bill could restrict patient access to compounded medications during drug shortages, impose new limitations on 503A pharmacies, and disproportionately affect legitimate compounders while failing to address bad actors. The episode also unpacks the legislation's connection to GLP-1 demand, adverse event reporting, and the bipartisan politics surrounding the bill, while encouraging listeners to stay engaged in APC's advocacy efforts.

This episode we look at some of the latest compounding news, and then we’ve got a deep dive into state-level legislation with the Leading Ladies of Pharmacy Compounding Advocacy. What bills are being introduced? What do they really mean when you read the detail? How will they affect state policies, and what could come next? And, of course, how are APC and compounding pharmacies fighting back against the bad bills that put patients at risk? If you’re a compounder, if you have patients who use compounded medications, or if you’re a patient yourself, you’ll want to hear this. Links from the podcast: The FDA statement on excluding GLP-1s from bulk compounding: https://fllw.me/491oGl3 FDA Law Blog on the state of peptide compounding: https://fllw.me/4cpFF2C (part 1), https://fllw.me/4nxd13G (part 2) Is It Legit? to find a state-licensed compounding pharmacy: https://a4pc.org/isitlegit Join APC! https://a4pc.org/join

This episode we look at a bunch of statements from the FDA and from HHS Secretary Robert F. Kennedy, Jr. And of course there are peptides to talk about these days. Does anyone really know what’s going on with those? Our deep dive is a special one: Our guest is Al Carter, the CEO of the National Association of Boards of Pharmacy, and he gives us a totally different perspective on the regulatory landscape at the level that affects pharmacists every day. Links from the podcast: The latest FDA statement on DTE: https://fllw.me/4sL6zXw The Coalition for Compounding Excellence’s first audit process guide (compounding records and quality control): https://fllw.me/3Oew1qr FDA Law Blog on the state of peptide compounding: https://fllw.me/4cpFF2C National Association of Boards of Pharmacy: https://nabp.pharmacy Join APC! https://a4pc.org/join

This week we look at a somewhat confusing, possibly problematic FDA statement, as well as the anti-compounding bills popping up across the country. Our Deep Dive this week is a hot topic: AI in pharmacies — how it’s being used successfully, but also how you can use it to streamline your workflow and, yes, even increase your bottom line. Our expert will tell you what to look for, and what easy pitfall you need to avoid. Links from the podcast: The troublesome FDA statement: https://fllw.me/4utzQIw APC’s Snapshot of Pharmacy Compounding: https://a4pc.org/snapshot Read more about the 2002 Supreme Court case "Thompson v. Western States Medical Center": https://www.oyez.org/cases/2001/01-344 TJM Labs: https://tjmlabs.com Join APC: https://a4pc.org/join

In this edition of Essential, we look at two major issues facing pharmacy compounding. First is a state-by-state effort by pharma companies to pass laws restricting compounding, and second is a cryptic statement from the FDA about possible limitations on compounding with GLP-1 ingredients. They’re both Very Big Deals for pharmacists across the country. Links FDA statement on GLP-1 drugs: https://www.fda.gov/news-events/press-announcements/fda-intends-take-action-against-non-fda-approved-glp-1-drugs … and APC’s response: https://a4pc.org/news/apc-responds-to-fdas-glp-1-statement Stay up to date on our state Compounding Defense Initiative: compounding.com Join APC today: https://a4pc.org/membership Find us on social: LinkedIn: https://www.linkedin.com/company/a4pcrx/ Facebook: https://www.facebook.com/a4pcrx/ Instagram: https://www.instagram.com/a4pcrx/